PURPOSE: Sphingolipids play important roles in apoptosis and cell proliferation. Sphingosine kinase 1 (SphK1) expression has a prognostic impact in primary breast cancer, but its predictive value is currently unknown. METHODS: A total of 112 breast cancer specimens from a prospective neoadjuvant chemotherapy trial (GeparDuo) were studied. Using tissue microarrays of pre-treatment core cut biopsies, we determined the expression of SphK1 by immunohistochemistry. The upper quartile of the cohort according to an immune reactive score of SphK1 was used as cutoff for high expression. RESULTS: We observed a larger number of samples with high SphK1 expression among ER-negative cancers (36.8 vs. 20.5 % among ER-positive cancers; Fisher test p = 0.073). Eighteen of the 112 patients demonstrated a pathological complete response. A significant predictive value for pathological complete response was observed for ER negativity (p = 0.003), young age (p = 0.037), and high tumor grade (p = 0.049). An increased pCR rate was observed in tumors with high SphK1 expression within the luminal subtype (26.7 vs. 5.8 %; Fisher test p = 0.040). No significant difference in survival was detected according to SphK1 expression. CONCLUSIONS: Our results suggest that SphK1 may be a predictive factor for pCR after neoadjuvant treatment in luminal type breast cancers and warrants further investigation.
PURPOSE:Sphingolipids play important roles in apoptosis and cell proliferation. Sphingosine kinase 1 (SphK1) expression has a prognostic impact in primary breast cancer, but its predictive value is currently unknown. METHODS: A total of 112 breast cancer specimens from a prospective neoadjuvant chemotherapy trial (GeparDuo) were studied. Using tissue microarrays of pre-treatment core cut biopsies, we determined the expression of SphK1 by immunohistochemistry. The upper quartile of the cohort according to an immune reactive score of SphK1 was used as cutoff for high expression. RESULTS: We observed a larger number of samples with high SphK1 expression among ER-negative cancers (36.8 vs. 20.5 % among ER-positive cancers; Fisher test p = 0.073). Eighteen of the 112 patients demonstrated a pathological complete response. A significant predictive value for pathological complete response was observed for ER negativity (p = 0.003), young age (p = 0.037), and high tumor grade (p = 0.049). An increased pCR rate was observed in tumors with high SphK1 expression within the luminal subtype (26.7 vs. 5.8 %; Fisher test p = 0.040). No significant difference in survival was detected according to SphK1 expression. CONCLUSIONS: Our results suggest that SphK1 may be a predictive factor for pCR after neoadjuvant treatment in luminal type breast cancers and warrants further investigation.
Authors: Alvin J X Lee; Rebecca Roylance; Jil Sander; Patricia Gorman; David Endesfelder; Maik Kschischo; Neil P Jones; Philip East; Barbara Nicke; Stefka Spassieva; Lina M Obeid; Nicolai Juul Birkbak; Zoltan Szallasi; Nicole C McKnight; Andrew J Rowan; Valerie Speirs; Andrew M Hanby; Julian Downward; Sharon A Tooze; Charles Swanton Journal: J Pathol Date: 2011-10-19 Impact factor: 7.996
Authors: Kazuaki Takabe; Roger H Kim; Jeremy C Allegood; Poulami Mitra; Subramaniam Ramachandran; Masayuki Nagahashi; Kuzhuvelil B Harikumar; Nitai C Hait; Sheldon Milstien; Sarah Spiegel Journal: J Biol Chem Date: 2010-01-28 Impact factor: 5.157
Authors: Silvia Darb-Esfahani; Sibylle Loibl; Berit M Müller; Marc Roller; Carsten Denkert; Martina Komor; Karsten Schlüns; Jens Uwe Blohmer; Jan Budczies; Bernd Gerber; Aurelia Noske; Andreas du Bois; Wilko Weichert; Christian Jackisch; Manfred Dietel; Klaus Richter; Manfred Kaufmann; Gunter von Minckwitz Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466
Authors: Keith R Stayrook; Justin K Mack; Donna Cerabona; Daniel F Edwards; Hai H Bui; Maria Niewolna; Pierrick Gj Fournier; Khalid S Mohammad; David L Waning; Theresa A Guise Journal: Bonekey Rep Date: 2015-07-08
Authors: Liang Zhang; Xiaoen Wang; Andrea J Bullock; Marcella Callea; Harleen Shah; Jiaxi Song; Kelli Moreno; Barbara Visentin; Douglas Deutschman; David C Alsop; Michael B Atkins; James W Mier; Sabina Signoretti; Manoj Bhasin; Roger A Sabbadini; Rupal S Bhatt Journal: Clin Cancer Res Date: 2015-01-14 Impact factor: 12.531
Authors: Daniel Yagoub; Marc R Wilkins; Angelina J Lay; Dominik C Kaczorowski; Diana Hatoum; Sarah Bajan; Gyorgy Hutvagner; Jack H Lai; Wengen Wu; Rosetta Martiniello-Wilks; Pu Xia; Eileen M McGowan Journal: Mol Endocrinol Date: 2014-09-12